Related Experiment Videos
[Assessment off-label prescribing in Dermatology]
D Picard1, P Carvalho, C Bonnavia
1Clinique Dermatologique, CHU de Rouen.
Annales De Dermatologie Et De Venereologie
|July 5, 2003
Summary
French dermatologists frequently issue off-label prescriptions, often for inflammatory conditions, but these are rarely supported by strong evidence-based medicine data. This practice impacts drug reimbursement policies.
Area of Science:
- Dermatology
- Pharmacology
- Health Policy
Context:
- French National Health Insurance policy denies reimbursement for off-label drug use.
- A dermatology department in France was studied to assess prescription practices.
Purpose:
- Quantify the incidence of off-label prescriptions in a French dermatology department.
- Characterize the indications and treatments involved in off-label prescribing.
- Evaluate the evidence base supporting these off-label prescriptions.
Summary:
- 14% of prescriptions were off-label, primarily for inflammatory and hypersensitivity dermatoses.
- Topical corticosteroids and methotrexate were common off-label treatments.
- 70% of off-label prescriptions lacked strong evidence-based medicine support, often prescribed by senior physicians.
Impact:
- Highlights a significant use of unproven off-label treatments in dermatology.
- Raises questions about current prescribing practices and adherence to evidence-based medicine.
- Informs potential policy adjustments regarding off-label drug use and reimbursement.